Genelux (NASDAQ:GNLX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLX) from a sell rating to a hold rating in a research report report published on Saturday morning.

A number of other analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research note on Thursday, January 22nd. Benchmark reduced their price objective on Genelux from $23.00 to $20.00 and set a “speculative buy” rating for the company in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Genelux in a research note on Monday, January 5th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $20.40.

Genelux Trading Up 3.3%

Shares of Genelux stock opened at $2.48 on Friday. The firm has a market capitalization of $111.13 million, a PE ratio of -2.88 and a beta of 0.15. Genelux has a twelve month low of $1.99 and a twelve month high of $8.53. The firm’s 50-day moving average price is $2.68 and its 200 day moving average price is $4.14.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.01 million during the quarter. On average, sell-side analysts predict that Genelux will post -0.88 EPS for the current fiscal year.

Insider Buying and Selling at Genelux

In other news, Director John Thomas sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $2.90, for a total value of $29,000.00. Following the completion of the sale, the director directly owned 482,784 shares in the company, valued at $1,400,073.60. This represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Genelux

A number of institutional investors have recently added to or reduced their stakes in the stock. Flputnam Investment Management Co. boosted its stake in Genelux by 708.1% during the third quarter. Flputnam Investment Management Co. now owns 300,290 shares of the company’s stock worth $1,261,000 after buying an additional 263,131 shares during the last quarter. MAI Capital Management increased its stake in shares of Genelux by 66,161.3% in the 2nd quarter. MAI Capital Management now owns 236,553 shares of the company’s stock worth $679,000 after acquiring an additional 236,196 shares during the last quarter. Global Retirement Partners LLC purchased a new position in shares of Genelux during the 2nd quarter worth $656,000. Goldman Sachs Group Inc. raised its holdings in shares of Genelux by 451.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 183,807 shares of the company’s stock worth $801,000 after acquiring an additional 150,463 shares during the period. Finally, 683 Capital Management LLC acquired a new position in shares of Genelux during the 4th quarter valued at about $572,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.